Mairs and Power's LLY Position Overview
Mairs and Power (via Mairs & Power INC) currently holds 358.2K shares of Eli Lilly and Company (LLY) worth $273.29 M, representing 2.57% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Mairs and Power has maintained a long-term strategic position in LLY, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 468.7K shares. Largest reduction occurred in Q1 2019, reducing 156.4K shares.
Analysis based on 13F filings available since 2013 Q2
Mairs and Power's Eli Lilly and Company (LLY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Eli Lilly and Company (LLY) Trades by Mairs and Power
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +282,499 | Add 0.00% | 282,498 | $49.12 |
| Q3 2013 | +14,161 | Add 5.01% | 296,659 | $50.33 |
| Q4 2013 | +6,578 | Add 2.22% | 303,237 | $51.00 |
| Q1 2014 | -10,233 | Reduce 3.37% | 293,004 | $58.86 |
| Q2 2014 | -1,704 | Reduce 0.58% | 291,300 | $62.17 |
| Q3 2014 | -1,473 | Reduce 0.51% | 289,827 | $64.85 |
| Q4 2014 | -2,370 | Reduce 0.82% | 287,457 | $68.99 |
| Q1 2015 | -838 | Reduce 0.29% | 286,619 | $72.65 |
| Q2 2015 | -18,350 | Reduce 6.40% | 268,269 | $83.49 |
| Q3 2015 | -44,688 | Reduce 16.66% | 223,581 | $83.69 |
| Q4 2015 | -2,377 | Reduce 1.06% | 221,204 | $84.26 |
| Q1 2016 | -1,069 | Reduce 0.48% | 220,135 | $72.01 |
| Q2 2016 | +26,935 | Add 12.24% | 247,070 | $78.75 |
| Q3 2016 | -4,900 | Reduce 1.98% | 242,170 | $80.26 |
| Q4 2016 | +8,308 | Add 3.43% | 250,478 | $73.55 |
| Q1 2017 | +468,730 | Add 187.13% | 719,208 | $84.11 |
| Q2 2017 | +152,628 | Add 21.22% | 871,836 | $82.30 |
| Q3 2017 | +105,113 | Add 12.06% | 976,949 | $85.54 |
| Q4 2017 | +37,532 | Add 3.84% | 1.01 M | $84.46 |
| Q1 2018 | +24,812 | Add 2.45% | 1.04 M | $77.37 |
| Q2 2018 | -2,815 | Reduce 0.27% | 1.04 M | $85.33 |
| Q3 2018 | -98,300 | Reduce 9.48% | 938,178 | $107.31 |
| Q4 2018 | -93,469 | Reduce 9.96% | 844,709 | $115.72 |
| Q1 2019 | -156,371 | Reduce 18.51% | 688,338 | $129.76 |
| Q2 2019 | -11,432 | Reduce 1.66% | 676,906 | $110.79 |
| Q3 2019 | +45,647 | Add 6.74% | 722,553 | $111.83 |
| Q4 2019 | +131,851 | Add 18.25% | 854,404 | $131.43 |
| Q1 2020 | -48,325 | Reduce 5.66% | 806,079 | $138.72 |
| Q2 2020 | -104,547 | Reduce 12.97% | 701,532 | $164.18 |
| Q3 2020 | -14,368 | Reduce 2.05% | 687,164 | $148.02 |
| Q4 2020 | +25,912 | Add 3.77% | 713,076 | $168.84 |
| Q1 2021 | -28,342 | Reduce 3.97% | 684,734 | $186.82 |
| Q2 2021 | -8,068 | Reduce 1.18% | 676,666 | $229.52 |
| Q3 2021 | -13,461 | Reduce 1.99% | 663,205 | $231.05 |
| Q4 2021 | -191 | Reduce 0.03% | 663,014 | $276.22 |
| Q1 2022 | -11,502 | Reduce 1.73% | 651,512 | $286.37 |
| Q2 2022 | -127,268 | Reduce 19.53% | 524,244 | $324.23 |
| Q3 2022 | -26,191 | Reduce 5.00% | 498,053 | $323.35 |
| Q4 2022 | -15,205 | Reduce 3.05% | 482,848 | $365.84 |
| Q1 2023 | +65,590 | Add 13.58% | 548,438 | $343.42 |
| Q2 2023 | -73,617 | Reduce 13.42% | 474,821 | $468.98 |
| Q3 2023 | -48,513 | Reduce 10.22% | 426,308 | $537.13 |
| Q4 2023 | -33,619 | Reduce 7.89% | 392,689 | $582.92 |
| Q1 2024 | -28,222 | Reduce 7.19% | 364,467 | $777.96 |
| Q2 2024 | -14,317 | Reduce 3.93% | 350,150 | $905.38 |
| Q3 2024 | -8,189 | Reduce 2.34% | 341,961 | $885.94 |
| Q4 2024 | -2,694 | Reduce 0.79% | 339,267 | $772.00 |
| Q1 2025 | +25,526 | Add 7.52% | 364,793 | $825.91 |
| Q2 2025 | +534 | Add 0.15% | 365,327 | $779.53 |
| Q3 2025 | -7,150 | Reduce 1.96% | 358,177 | $763.00 |
Mairs and Power's Eli Lilly and Company Investment FAQs
Mairs and Power first purchased Eli Lilly and Company (LLY) in Q2 2013, acquiring 282,498 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power has held Eli Lilly and Company (LLY) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's largest addition to Eli Lilly and Company (LLY) was in Q1 2017, adding 719,208 shares worth $60.49 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Mairs and Power's firm, Mairs & Power INC, owns 358,177 shares of Eli Lilly and Company (LLY), valued at approximately $273.29 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Eli Lilly and Company (LLY) represents approximately 2.57% of Mairs and Power's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Mairs and Power's peak holding in Eli Lilly and Company (LLY) was 1,039,293 shares, as reported at the end of Q1 2018. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.